Navigation Links
BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
Date:12/16/2013

JERUSALEM, Dec. 16, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML). The early results show that BL-8040, as a stand-alone therapy and in combination with high-dose Cytarabine (Ara-C), is safe at all doses tested to date, and triggers substantial mobilization of cancer cells from the bone marrow to the peripheral blood, thereby increasing the vulnerability of the cells to chemotherapy treatment. In addition, signs of robust apoptosis (cell death) of cancer cells were observed following administration of the higher doses tested to date. The study has not yet reached the highest planned doses, suggesting that a strengthening of BL-8040's effects may be observed in future dosing cohorts.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769 )

The Phase 2 trial is a multicenter, open-label study under an IND, and is designed to evaluate the safety and efficacy of repeated escalating doses of BL-8040 in adult patients with relapsed or refractory AML. The primary endpoints of the study are to assess the safety and tolerability of BL-8040. Secondary endpoints include the pharmacokinetic profile of the drug and an efficacy evaluation, indicated by the extent of mobilization of cancer cells from the bone marrow to the peripheral blood, the level of cancer cell death (apoptosis) and clinical responses.

Eight patients have already been enrolled in the study, out of a total expected enrollment of up to 50 patients at eight clinical sites in the U.S. and Isr
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
2. BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
3. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
4. BioLineRx Reports Third Quarter 2013 Financial Results
5. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
6. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
7. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
8. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
9. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
10. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
11. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- Report Details   Translational ... progress, and predicted revenues ,Where is the market for ... prospects for this market and related technologies? Visiongain,s brand ... to 2025, discussing data, opportunities and prospects. ... medicine : cell-based therapies that aim to restore function ...
(Date:2/27/2015)... OF PRUSSIA, Pa. , Feb. 27, 2015 /PRNewswire/ ... of its ongoing commitment to the global bleeding disorders ... is donating 2 million international units (IUs) of protein ... is an international not-for- profit organization which has worked ... other inherited bleeding disorders. The donation supports the WFH,s ...
(Date:2/27/2015)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the fourth quarter and full year ended December ... year for PTC. We are now a growing commercial-stage ... in the rare disease space," stated Stuart W. Peltz, ... proud to bring the first treatment for Duchenne muscular ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11
(Date:3/1/2015)... March 01, 2015 The number of ... over the past few weeks in two New Jersey ... filing claims, the Firm announces. , A Case ... in the Bergen County proceeding established for products manufactured ... a few weeks earlier, when 90 fewer cases had ...
(Date:3/1/2015)... Aliso Viejo, California (PRWEB) March 01, 2015 ... have announced a new transition pack for ... users to add accordion style transitions to any FCPX ... Studios. “We’ve given our users the tools needed to ... FCPX media.” , The user gets many different controls ...
(Date:2/28/2015)... 01, 2015 Heart diseases are on ... percent of urban adult population and 5 percent of ... diseases and 20-30 percent of them require specialized investigation ... and coronary vascular diseases (CVD). , A division of ... market research report titled “Indian Coronary Stent Market Forecast ...
(Date:2/28/2015)... The Heart Fit Clinic started doing ... the machine. The Heart Fit Clinic is also selling ... franchise model. The goal is to scale the business ... To buy External Counterpulsation machines can be ... through this process and achieve the desired results. ...
(Date:2/28/2015)... 2015 Vancouver personal injury lawyers at Jiwa ... affected by time limits. They stated that in many cases, ... or even nullify it. Many a time, delays in making ... rights under BC law. As a result, experts at Jiwa ... should consult a personal injury lawyer in order to know ...
Breaking Medicine News(10 mins):Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2
... Steven Reinberg HealthDay Reporter , TUESDAY, Jan. 10 (HealthDay ... -- defined as men who down five or more drinks at ... one time, federal researchers reported Tuesday. Of the 17 percent ... 24 years old. But those 65 and older engage in the ...
... , INDIANAPOLIS -- The School of Science at Indiana ... Modeling and Computational Science, an interdisciplinary endeavor dedicated to ... the environment, and computer science. iM2CS,s parallel mission is ... the scientific issues with which they will be faced. ...
... , TUESDAY, Jan. 10 (HealthDay News) -- Dutch researchers ... the drug Nexavar (sorafenib) in fighting a tough-to-treat form ... experimental drug known as ganetespib showed promise in laboratory ... studies were to be presented Tuesday at an American ...
... Island Hospital has found that collaborative ,behavioral management may ... users who are paroled. The findings have important implications ... U.S. community correctional population. The study is published in ... of print. In the U.S., over 700,000 inmates ...
... January issue of Health Affairs assesses real-world ... chronic disease that affects nearly 26 million Americans. ... systematically reviewed the published literature and analyzed 28 studies ... trial in real-world settings. Published in 2002, this major ...
... HealthDay Reporter , MONDAY, Jan. 9 (HealthDay News) -- The ... the risk of heart attack, a new review finds. ... trials involving Pradaxa that included more than 30,000 patients. This ... to tease out a pattern that might not show up ...
Cached Medicine News:Health News:One in Six Americans Binge Drink: CDC 2Health News:One in Six Americans Binge Drink: CDC 3Health News:Revealing causality 2Health News:Mixed News on Tough-to-Treat Lung Cancer 2Health News:Mixed News on Tough-to-Treat Lung Cancer 3Health News:Behavioral management to reduce substance abuse, crime and re-arrest for drug-involved parolees 2Health News:Behavioral management to reduce substance abuse, crime and re-arrest for drug-involved parolees 3Health News:Diabetes study shines spotlight on lifestyle interventions 2Health News:Diabetes study shines spotlight on lifestyle interventions 3Health News:New Blood Thinner Linked to Higher Heart Attack Risk 2Health News:New Blood Thinner Linked to Higher Heart Attack Risk 3
Test for prostatic acid phosphatase...
For the quantitative measurement of human prostatic acid phosphatase (PAP) in human serum....
... a Windows 2000 PC based EEG with ... and software. EEG-9200 provides high quality performance ... in the sleep lab or EEG lab. ... the electrically noisy OR or ICU. Neurofax ...
... the first magnetic stimulator to offer the ... It is designed to provide the simplest ... routine (at the same time, it may ... can control operations without moving away from ...
Medicine Products: